Overcoming Biological and Technical Challenges to Achieve HIgh Dose Drug Delivery to the Lungs
Hickey AJ.
Respiratory Drug Delivery 2024. Volume 1, 2024: 130-136.
Abstract:
High dose delivery of inhaled drugs is demanded by low potency pharmacological agents most notably those used to treat infectious disease. The requirement of the addition of excipients in preparing drugs and biologics for a variety of pulmonary diseases may also require the delivery of a high total powder dose to the lungs. Drug products and their particle or droplet delivery systems, dry powder inhalers (DPIs) or nebulizers, are capable of delivering high doses either as boluses on a single breath or as steady state aerosols by passive inhalation. The interaction of the formulation and device with the patient inspiratory flow are the determinants of effective pulmonary drug delivery and the subsequent navigation of the barriers to entry to the lungs, transition to the site of deposition and dissolution require consideration with respect to safety and efficacy.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
